Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Galy, Anne  [Clear All Filters]
2013
Kaufmann KB, Büning H, Galy A, Schambach A, Grez M. Gene therapy on the move. EMBO Mol Med. 2013.
Saliba J, Hamidi S, Lenglet G, Langlois T, Yin J, Cabagnols X, Secardin L, Legrand C, Galy A, Opolon P, et al. Heterozygous and Homozygous JAK2(V617F) States Modeled by Induced Pluripotent Stem Cells from Myeloproliferative Neoplasm Patients. PLoS One. 2013;8(9):e74257.
Fenard D, Ingrao D, Seye A, Buisset J, Genries S, Martin S, Kichler A, Galy A. Vectofusin-1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells. Mol Ther Nucleic Acids. 2013;2:e90.
2014
Holic N, Seye AKhalil, Majdoul S, Martin S, Merten O-W, Galy A, Fenard D. Influence of mildly acidic pH conditions on the production of lentiviral and retroviral vectors. Hum Gene Ther Clin Dev. 2014.
2015
Abina SHacein-Bey, H Gaspar B, Blondeau J, Caccavelli L, Charrier S, Buckland K, Picard C, Six E, Himoudi N, Gilmour K, et al. Outcomes Following Gene Therapy in Patients With Severe Wiskott-Aldrich Syndrome. JAMA. 2015;313(15):1550-1563.
2020
Six E, Guilloux A, Denis A, Lecoules A, Magnani A, Vilette R, Male F, Cagnard N, Delville M, Magrin E, et al. Clonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programs. Blood. 2020.
2023
Corre G, Galy A. Evaluation of diversity indices to estimate clonal dominance in gene therapy studies. Mol Ther Methods Clin Dev. 2023;29:418-425.
Labrosse R, Chu J, Armant M, Everett JK, Pellin D, Kareddy N, Frelinger AL, Henderson LA, O'Connell AE, Biswas A, et al. Outcomes of Hematopoietic Stem Cell Gene Therapy for Wiskott-Aldrich Syndrome. Blood. 2023.
Galy A, Dewannieux M. Recent advances in hematopoietic gene therapy for genetic disorders. Arch Pediatr. 2023;30(8S1):8S24-8S31.
2024
Das S, Rruga F, Montepeloso A, Dimartino A, Spadini S, Corre G, Patel J, Cavalca E, Ferro F, Gatti A, et al. An empowered, clinically-viable hematopoietic stem cell gene therapy approach for the treatment of multisystemic Mucopolysaccharidosis Type II. Mol Ther. 2024.